This Stock Is Up Over 52,700% Since Founding. Should Investors Buy After Its 36% Decline?

The setup is less about a classic valuation rerate and more about a multi-year earnings quality reset. Danaher’s core issue was not structural obsolescence but an abnormal demand surge that distorted the base, followed by a normalization period that made organic growth look worse than it really was. That matters because once revenue growth re-accelerates off a depressed comp, operating leverage can reassert quickly, especially in a portfolio model like Danaher’s where integration discipline and pricing power typically show up with a lag.

The Masimo deal is strategically useful beyond the headline revenue addition. It gives Danaher a stronger diagnostics mix at a time when healthcare buyers are favoring sticky, consumable-adjacent workflows over more cyclical instrument demand, and the cash-funded structure avoids a near-term EPS overhang from equity dilution. The second-order read-through is that Danaher is signaling confidence in its balance sheet and acquisition pipeline; that can support a higher floor on the multiple if management can keep turning cash flow into bolt-ons that are immediately accretive.

The market is likely underestimating how much of the discount is sentiment-driven rather than fundamentals-driven. A sub-23x forward multiple is not cheap in isolation, but for a business with mid-to-high single-digit earnings growth, >$5B of free cash flow, and a credible M&A catalyst path, the issue is whether investors will pay for normalization before China stabilizes. The key risk is that China weakness and integration risk could delay the inflection by 2-4 quarters, which would keep the stock range-bound even if the long-term thesis remains intact.

From a trade perspective, this is better expressed as a gradual long than an aggressive momentum chase. The asymmetry improves if post-deal execution is clean and management raises synergy or accretion guidance over the next two earnings prints; if not, the stock can remain a value trap despite better headline growth. The contrarian angle is that the consensus may be overfocusing on the valuation discount and underweighting the fact that Danaher rarely stays cheap once organic growth turns positive and capital deployment regains momentum.